OUR TEAM
LAB 2 WRITEUP
Descriptive Statistics
Experiment 1 (rat)
Due to FDA Regulations an animal test group was extablished to determine the effectiveness of LPS on inflamitin.
*Due to the sample size a mode could not be determined.

Inflammotin density in rat trials 
LPS Dosage 
Mean (pg/mL) 
Median (pg/mL) 
Mode (pg/mL) 
Standard Deviation 
Standard Error 
0mg 
10.5 
9.24 
* 
2.23 
0.995 
10mg 
11.1 
8.99 
* 
7.40 
3.31 
Experiment 2(human)
People of age 5585 who meet general health guidelines were used in this study. Patients with inflammation related past medical diagnoses where not used in the study do to the risk of experimental error.
*Due to the sample size a mode could not be determined.

Inflammotin density in Human trials 
LPS Dosage 
Mean (pg/mL) 
Median (pg/mL) 
Mode (pg/mL) 
Standard Deviation 
Standard Error 
0mg 
3.83 
4.12 
* 
1.52 
0.481 
5mg 
8.93 
8.98 
* 
1.59 
0.503 
10mg 
61.6 
73.4 
* 
30.1 
9.52 
15mg 
658 
723 
* 
213 
67.4 
Results
Experiment 1(Rats)
Statistic table representing data gathered in trials
Inferential Statistics
Determination of the study at the end of trial per dosage.
Inflammotin protein levels present in Rats when allowing the LPS dosage to vary.
Experiment 2 (Humans)
Statistic table representing data gathered in trials
Inferential Statistics
Determination of the study at the end of trial per dosage.
Posthoc Tests 
ttest value 
Corrected significant pvalue 
Significant? 
0mg vs. 5mg 
8.59631E07 
0.008333333 
yes 
0mg vs. 10mg 
9.94377E06 
0.008333333 
yes 
0mg vs. 15mg 
1.39436E08 
0.008333333 
yes 
5mg vs. 10mg 
3.01859E05 
0.008333333 
yes 
5mg vs. 15mg 
1.57101E08 
0.008333333 
yes 
10mg vs. 15mg 
6.4824E08 
0.008333333 
yes 
Annova Summary  Human Trials
Groups 
Count 
Sum 
Average 
Variance 
0 Pills 
5 
510.3 
102.06 
2.488 
1 Pill 
5 
503.6 
100.72 
0.977 
2 Pills 
5 
494 
98.8 
0.1 
Annova  Human Trials
Source of Variation 
SS 
df 
MS 
F 
Pvalue 
F crit 
Between Groups 
26.84933333 
2 
13.42466667 
11.2970547 
0.001742106 
3.885293835 
Within Groups 
14.26 
12 
1.188333333 










Total 
41.10933333 
14 




Inflammotin protein levels present in Rats when allowing the LPS dosage to vary.
Analysis
Experiment 1
The results of the clinical trial on rats proved inconclusive as the tested dose did not provide consistent results. The attributed test group is 0mg to 10mg there is no clear correlation.
The rate provided with a sugar pill resulted in an overall average of 10.5 pg/ml, a value 1.74 pg/ml higher then the lowest result and 3.0 pg/ml lower then the highest result.
The spread of these results leads to a standard deviation of 2.23 pg/ml, and a standard error of .995 pg/ml.
The average rate of 10mg is 11.1 pg/ml, a value 11.24 pg/ml below the greatest value and, 7.55 pg/ml above the lowest value.
The spread of these results leads to a standard deviation of 7.40 pg/ml, and a standard error of 3.31 pg/ml
The culmination of these results determine that the effect of the drug is inconclusive.
Experiment 2
The experimental results in Humans suggest that the concentration of Inflammotin protein is strongly dependent on the LPS dosage administered. First, an anova was performed which showed the difference between treatments to be significant, with a pvalue of approximately 0.00174. Next, posthoc tests were performed. Applying the Bonferroni correction to the initial critical value of 0.05 gave a critical pvalue of 8.33*10^{3}. For each of the treatment groups compared, the pvalue was significantly lower than the adjusted critical value, confirming the implications of the anova. One important take away from this analysis is that, according to the Human data, there is a logarithmic dependence of Inflammotin concentration on LPS dosage. In other words, each 5mg increase in LPS dosage saw an order of magnitude increase in Inflammotin concentration.
Summary/Discussion
The purpose of the first laboratory experiment with rats acted as the control for this experiment. The control was important in determining if the decrease in inflammation was a placebo affect or a result of taking LPS. The conclusion for this experiment would result in LPS having a placebo affect not a biological affect if the rats had no difference in the concentration of the protein inflammotin in the body. When comparing rats who were given 10mg of LPS and rats who were given 0mg of LPS. After the calculation of the ttest between the results of rats who were given 0mg and 10mg, resulted in a pvalue greater than 0.05 making the results insignificant. Concluding that the pill LPS does not have a consistent affect on the body, due to varying results of inflammotin in the body.
The purpose of the second laboratory experiment with humans was used to see if different dosages of LPS had an effect on inflammotin levels in the body. This was done in order to see if the elderly could take less LPS and still have the same affect on their inflammotin levels. The conclusion for this experiment would result in no correlation between inflammotin levels and LPS dosage if the ttests between dosage intervals resulted in a pvalue that is greater than 0.05 or if all of the intervals were considered significant. After the calculation of the ttest's between 0mg5mg, 0mg10mg, 0mg15mg, 5mg10mg, 5mg15mg, 10mg15mg; all the intervals were considered significant. The inflammotin levels did increase with the increase in dosage but, so did the source of error and standard deviation, causing the results to be unreliable. Therefore a specific dosage of LPS in the interval between 0mg15mg was unable to be determined.
